###begin article-title 0
###xml 12 17 <span type="species:ncbi:10090">mouse</span>
Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence
###end article-title 0
###begin p 1
###xml 515 518 515 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 538 542 538 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 491 496 <span type="species:ncbi:9606">human</span>
###xml 561 567 <span type="species:ncbi:10090">murine</span>
###xml 1462 1467 <span type="species:ncbi:10090">mouse</span>
###xml 1556 1561 <span type="species:ncbi:9606">human</span>
Diversity in the pathophysiology of breast cancer frustrates therapeutic progress. We need to understand how mechanisms activated by specific combinations of oncogenes, tumor suppressors, and hormonal signaling pathways govern response to therapy and prognosis. A recent series of investigations conducted by Chodosh and colleagues offers new insights into the similarities and differences between specific oncogenic pathways. Expression of three oncogenes relevant to pathways activated in human breast cancers (c-myc, activated neu and Wnt1) were targeted to murine mammary epithelial cells using the same transgenic tetracycline-responsive conditional gene expression system. While the individual transgenic lines demonstrate similarly high rates of tumor penetrance, rates of oncogene-independent tumor maintenance and recurrence following initial regression are significantly different, and are modifiable by mutations in specific cooperating oncogenes or loss of tumor suppressor gene expression. The experiments make three notable contributions. First, they illustrate that rates of tumor regression and recurrence following initial regression are dependent upon the pathways activated by the initiating oncogene. The experiments also demonstrate that altered expression or mutation of specific cooperating oncogenes or tumor suppressor genes results in different rates of tumor regression and recurrence. Finally, they exemplify the power of conditional mouse models for elucidating how specific molecular mechanisms give rise to the complexity of human cancer.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 575 576 575 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 577 578 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 298 303 <span type="species:ncbi:10090">mouse</span>
###xml 344 349 <span type="species:ncbi:9606">human</span>
###xml 558 573 <span type="species:ncbi:10090">transgenic mice</span>
###xml 780 785 <span type="species:ncbi:9606">human</span>
Cancer is a multistage process. Cells are selected after accumulating successive genetic lesions in oncogenes and tumor suppressor genes, resulting in independence from the normal restraints that regulate growth, proliferation, survival, differentiation and migration [1-5]. Conditional transgenic mouse models expressing oncogenes involved in human cancer pathways have revolutionized the way in which we define the contributions that these oncogenes lend to the process of tumorigenesis. Adaptation of the tetracycline-responsive gene expression system to transgenic mice [6-9] prepared the way for development of conditional models in which precise timing of oncogene exposure in specific tissues initiated events that model those that occur during the stepwise progression of human oncogenesis [10-18].
###end p 3
###begin p 4
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 801 807 801 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 808 810 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 842 848 842 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras </italic>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 880 888 880 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL </italic>
###xml 889 891 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1098 1102 1098 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc </italic>
###xml 1146 1148 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1168 1170 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1218 1222 1218 1222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc </italic>
###xml 1286 1290 1286 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras </italic>
###xml 1357 1361 1357 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras </italic>
###xml 1406 1410 1406 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras </italic>
###xml 1442 1446 1442 1446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc </italic>
A first application of these models was to study the potential for reversal of a dysplastic or malignant phenotype when expression of an initiating oncogene was downregulated. Determining the effect of loss of expression of the initiating oncogene establishes the requirement of the initiating oncogene for maintenance of preneoplasia and/or neoplasia. Experiments to date reveal provocative differences in preneoplastic or neoplastic reversal between different initiating oncogenes and target tissues. Reversibility of salivary oncogenesis initiated by expression of the complex oncoprotein Large Simian Virus 40 T antigen, which disrupts both pRB-related and p53 tumor suppressor pathways, is interrupted at a preneoplastic stage in a time-dependent manner [11]. In contrast, melanomas initiated by H-Ras [12], lung carcinomas initiated by K-Ras [13], and leukemia initiated by BCR-ABL [14] remain reversible through the neoplastic stage after expression of the initiating oncogene is downregulated. Reversibility in different tissues following downregulation of the single initiating oncogene c-myc can be compared in mammary adenocarcinomas [15] and in lymphomas [16]. Whereas 90% of the lymphomas regress after c-myc abrogation, regression of mammary adenocarcinomas is limited by ras mutation. Seventy-eight percent of mammary adenocarcinomas without ras mutation regress, while adenocarcinomas with ras mutation do not regress after c-myc downregulation.
###end p 4
###begin p 5
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
In these experiments neoplastic reversal is due either to rapid apoptosis of tumor cells [12-14,16] or to redifferentiation of cells causing arrest of proliferation and loss of malignant potential [16]. These models are important since they suggest that ablation of signaling from one oncogenic pathway may be sufficient to reverse a malignant phenotype. In some models it is possible that tumor cells expressing an oncogene may have undergone adaptive transcriptional changes that lead to their dependence on continued expression of the oncogene for growth and survival. These adaptive changes might not allow the tumor cells to switch to other proliferative pathways swiftly enough to prevent activation of apoptotic machinery [13].
###end p 5
###begin p 6
###xml 140 145 140 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 174 177 174 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 210 213 210 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 365 373 365 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL </italic>
###xml 395 402 395 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 523 531 523 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL </italic>
###xml 647 651 647 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc </italic>
###xml 685 689 685 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras </italic>
###xml 748 751 748 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
Oncogene-independent recurrent growth of tumors in animals with regressed primary tumors was reported in a small percentage of cases in the H-Ras-induced melanoma [12], in c-myc-induced lymphomas [16] and in c-myc-induced mammary adenocarcinomas [15]. Additionally, in a line of mice with longer leukemia latency, all mice in remission due to downregulation of the BCR-ABL transgene developed a BCR-ABL-independent, rapidly progressing, B-cell leukemia [14]. It was hypothesized that the prolonged exposure of the cells to BCR-ABL allowed for the development of secondary mutations that bypass reliance on the initial transforming event. In the c-myc mammary adenocarcinoma model, the ras mutation was identified as a genetic event that promotes c-myc-independent tumor growth [15].
###end p 6
###begin title 7
Reversibility and recurrence of mammary adenocarcinomas and metastases induced by activated Neu
###end title 7
###begin p 8
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Chodosh and colleagues have extended and amplified these studies by examining the reversibility and oncogene-independent recurrence of different initiating oncogenes in the same target tissue, the mammary gland (Fig. 1).
###end p 8
###begin p 9
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 753 758 <span type="species:ncbi:9606">human</span>
Transgenic mice with conditional expression of activated Neu in mammary epithelial cells were designed (MTB/TAN mice) to examine the dependence of continued oncogene expression on activated Neu-initiated tumors and metastases [19]. Expression of activated Neu causes hyperplastic abnormalities in the mammary ductal tree, in the ductal hyperplasia, and in the invasive mammary nodular carcinomas in 100% of the mice. Downregulation of activated Neu in double transgenic MTB/TAN female mice with mammary carcinomas showed that 94% of tumors are reversible and regress to a nonpalpable state. Even metastatic lesions are dependent on activated Neu for growth and also regress following abrogation of transgene expression. However, as frequently occurs in human cancers following initial therapeutic success, a significant percentage (63%) of the regressed cancers eventually recur.
###end p 9
###begin p 10
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
An intriguing feature of the experiments was the fact that the percentages of primary tumors and metastases demonstrating oncogene-independent maintenance was increased when they were first transplanted into syngeneic hosts before abrogation of transgene expression. Stromal cells surrounding tumors can secrete growth and survival factors (such as matrix metalloproteinases), which may promote cancer development, cancer progression, and cancer metastasis by altering the tumor environment [20]. For example, matrix metalloproteinases may act in transformation by inducing apoptosis in anchorage-dependent cells and/or by modifying cell cycle checkpoints through alterations in cell adhesion. The increase in primary tumors and metastases that resulted after transplantation illustrates that tumor regression did not necessarily occur after loss of oncogene expression. The increase raises the possibility that this model can be utilized to explore how the tumor environment can modify cancer cell behavior and how stromal changes are linked to primary epithelial cell oncogenic events.
###end p 10
###begin title 11
Loss of one p53 allele alters reversal and recurrence of Wnt-induced mammary adenocarcinomas
###end title 11
###begin p 12
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 233 238 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 460 465 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 965 966 965 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1011 1016 1011 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 186 201 <span type="species:ncbi:10090">transgenic mice</span>
###xml 248 252 <span type="species:ncbi:10090">mice</span>
###xml 738 742 <span type="species:ncbi:10090">mice</span>
Chodosh and colleagues used the same conditional system to examine the requirement of continued Wnt1 expression in the maintenance and recurrence of mammary cancers by developing double transgenic mice with conditional expression of Wnt1 (MTB/TWNT mice) [21]. In MTB/TWNT double transgenic females, induction of Wnt1 expression by doxycycline administration results in increased ductal side branching and in precocious lobuloalveolar development. Upon chronic Wnt1 exposure, ductal hyperplasia develops into invasive mammary adenocarcinomas that metastasize to the lung. Similar to activated Neu, abrogation of Wnt signaling by doxycycline withdrawal leads to rapid regression of mammary adenocarcinomas and lung metastases in 94% of the mice. But intriguingly, rates of tumor reoccurrence and the requirement for continued oncogene expression for tumor maintenance following transplantation were significantly different from those in the activated Neu model (Fig. 1). Tumors recur in only 29% of the regressed Wnt1 tumors, and all of the transplanted tumors and metastases regressed after loss of oncogene expression.
###end p 12
###begin p 13
###xml 209 213 209 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 306 311 306 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
As the next step, Chodosh and colleagues examined the role of the specific tumor suppressor gene p53 in oncogene-independent tumor maintenance and recurrence. Even though p53 is not required for regression of Wnt1-induced tumors, 40% of the tumors that develop in p53 heterozygous mice do not regress when Wnt1 is down-regulated, and a high percentage (76%) of the adenocarcinomas that do regress subsequently recur.
###end p 13
###begin title 14
Conclusion
###end title 14
###begin p 15
###xml 23 28 <span type="species:ncbi:10090">mouse</span>
Conditional transgenic mouse models allow investigators to model possible therapeutic consequences of oncogene downregulation on the maintenance of malignancy and recurrence. Oncogenic pathways can be examined in individual tissues and cancer systems to determine whether there will be oncogene-independent growth, and if so to which alternative pathways the cells turn in order to bypass oncogene dependence. Results from these experiments may suggest alternative or adjuvant therapies.
###end p 15
###begin p 16
###xml 346 349 346 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 575 578 575 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 749 754 749 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 1044 1047 1044 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 1098 1102 1098 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras </italic>
###xml 1354 1358 1354 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
Experiments by Chodosh and colleagues illustrate the power of conditional transgenic mouse systems to investigate the impact of different initiating oncogenes on mammary oncogenesis, on oncogene-independent tumor maintenance, and on recurrence following initial regression. The results exemplify the differences between oncogenes. While 56% of c-myc-induced mammary cancers demonstrate oncogene-independent tumor maintenance, only 6% of activated Neu-induced and Wnt1-induced mammary cancers demonstrate oncogene-independent tumor maintenance. While only a fraction of the c-myc-induced mammary cancers that regress after downregula-tion of oncogene expression subsequently recur, 63% of regressed activated Neu mammary cancers and 29% of regressed Wnt1 mammary cancers recur. The Chodosh laboratory also shows us examples of how mutations in cooperating oncogenes, changes in tumor environment, and loss of tumor suppressor gene expression can alter oncogene-independent tumor maintenance and recurrence. Oncogene-independent maintenance of c-myc-induced mammary adenocarcinomas is facilitated by ras mutation, the oncogene-independent maintenance of activated Neu-induced adenocarcinomas and metastases is altered when they are transplanted to a different environment, and p53 heterozygosity promotes oncogene-independent maintenance and recurrence of Wnt1-induced adenocarcinomas.
###end p 16
###begin p 17
###xml 835 837 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 153 158 <span type="species:ncbi:9606">human</span>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
###xml 492 497 <span type="species:ncbi:10090">mouse</span>
###xml 683 688 <span type="species:ncbi:9606">human</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
###xml 829 833 <span type="species:ncbi:10090">mice</span>
Further exploitation of conditional systems will provide even more detailed information on the diverse molecular mechanisms that act together to produce human cancer. It may be possible to explore earlier stages in the development of cancers using these conditional systems to determine whether premalignant lesions are present, and if so how they regress after oncogene downregulation. In addition to oncogene dependence, the development of the MTB mice, which allow direct targeting of the mouse mammary epithelial cells, allows for the study of other factors that contribute to mammary adenocarcinoma progression. For example, reproductive history is an important risk factor for human breast cancer. It has also been shown in mice that the number of pregnancies hastens the development of mammary adenocarcinoma in HER-2/neu mice [22]. The effect of multiple pregnancies and ovariectomy on tumor latency and cancer regression can also be examined in these models. Use of this knowledge should help us to understand the limitations of current therapies that target specific pathways and to promote development of new ones.
###end p 17
###begin title 18
Competing interests
###end title 18
###begin p 19
None declared.
###end p 19
###begin title 20
Abbreviations
###end title 20
###begin p 21
###xml 214 220 214 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NeuNT </italic>
###xml 221 231 221 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TetO-NeuNT</italic>
###xml 304 309 304 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 310 319 310 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TetO-Wnt1</italic>
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
###xml 33 37 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
###xml 252 257 <span type="species:ncbi:10090">mouse</span>
MTB = transgenic mouse line with MMTV-LTR-driven expression of reverse tetracycline-dependent transactivator 'Tet-On' in the mammary epithelium; TAN = transgenic mouse line with doxycycline-inducible expression of NeuNT (TetO-NeuNT); TWNT = transgenic mouse line with doxycycline-inducible expression of Wnt1 (TetO-Wnt1).
###end p 21
###begin article-title 22
The clonal evolution of tumor cell populations
###end article-title 22
###begin article-title 23
Molecular themes in oncogenesis
###end article-title 23
###begin article-title 24
Facts and theories concerning the mechanisms of carcinogenesis
###end article-title 24
###begin article-title 25
The hallmarks of cancer
###end article-title 25
###begin article-title 26
Commentary: is the concept of 'tumor promotion' a useful paradigm?
###end article-title 26
###begin article-title 27
###xml 39 54 <span type="species:ncbi:10090">transgenic mice</span>
Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter
###end article-title 27
###begin article-title 28
Efficacy of tetracycline-controlled gene expression is influenced by cell type: commentary
###end article-title 28
###begin article-title 29
###xml 84 99 <span type="species:ncbi:10090">transgenic mice</span>
Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice
###end article-title 29
###begin article-title 30
A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology
###end article-title 30
###begin article-title 31
###xml 71 86 <span type="species:ncbi:10090">transgenic mice</span>
Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene
###end article-title 31
###begin article-title 32
###xml 42 57 <span type="species:ncbi:10090">transgenic mice</span>
###xml 69 73 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen
###end article-title 32
###begin article-title 33
Essential role for oncogenic Ras in tumour maintenance
###end article-title 33
###begin article-title 34
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes
###end article-title 34
###begin article-title 35
Reversibility of acute B-cell leukaemia induced by BCR-ABL1
###end article-title 35
###begin article-title 36
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations
###end article-title 36
###begin article-title 37
Reversible tumorigenesis by MYC in hematopoietic lineages
###end article-title 37
###begin article-title 38
Sustained loss of a neoplastic phenotype by brief inactivation of MYC
###end article-title 38
###begin article-title 39
Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression
###end article-title 39
###begin article-title 40
###xml 59 74 <span type="species:ncbi:10090">transgenic mice</span>
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis
###end article-title 40
###begin article-title 41
The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter
###end article-title 41
###begin article-title 42
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis
###end article-title 42
###begin article-title 43
###xml 106 110 <span type="species:ncbi:10090">mice</span>
Number of pregnancies and ovariectomy modify mammary carcinoma development in transgenic HER-2/neu female mice
###end article-title 43
###begin title 44
Figures and Tables
###end title 44
###begin p 45
###xml 212 217 212 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 520 522 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 523 525 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 526 528 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 165 170 <span type="species:ncbi:10090">mouse</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
###xml 440 455 <span type="species:ncbi:10090">transgenic mice</span>
Comparison of the rates of penetrance, of maintenance after oncogene downregulation, and of recurrence after oncogene downregulation in three conditional transgenic mouse models of mammary carcinogenesis. In the Wnt1 group, the first bars depict the rates for p53 wildtype (p53+/+) mice and the final two bars for p53 heterozygote (p53+/-) mice. The rate of oncogene-independent explant maintenance for primary tumor and metastasis in Wnt1 transgenic mice was 0%. 1degrees, primary tumor; Met, metastasis. Adapted from [15,19,21].
###end p 45

